Show simple item record

dc.contributor.authorBlagg, J
dc.contributor.authorWorkman, P
dc.date.accessioned2017-07-19T15:35:43Z
dc.date.issued2017-07-10
dc.identifier.citationCancer cell, 2017, 32 (1), pp. 9 - 25
dc.identifier.issn1535-6108
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/725
dc.identifier.eissn1878-3686
dc.identifier.doi10.1016/j.ccell.2017.06.005
dc.description.abstractSmall-molecule chemical probes or tools have become progressively more important in recent years as valuable reagents to investigate fundamental biological mechanisms and processes causing disease, including cancer. Chemical probes have also achieved greater prominence alongside complementary biological reagents for target validation in drug discovery. However, there is evidence of widespread continuing misuse and promulgation of poor-quality and insufficiently selective chemical probes, perpetuating a worrisome and misleading pollution of the scientific literature. We discuss current challenges with the selection and use of chemical probes, and suggest how biologists can and should be more discriminating in the probes they employ.
dc.formatPrint
dc.format.extent9 - 25
dc.languageeng
dc.language.isoeng
dc.publisherCELL PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectMolecular Probes
dc.subjectResearch Design
dc.titleChoose and Use Your Chemical Probe Wisely to Explore Cancer Biology.
dc.typeJournal Article
dcterms.dateAccepted2017-06-09
rioxxterms.versionofrecord10.1016/j.ccell.2017.06.005
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer cell
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.publication-statusPublished
pubs.volume32
pubs.embargo.termsNo embargo
icr.researchteamMedicinal Chemistry 1
dc.contributor.icrauthorWorkman, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0